AlphaCentric Advisors LLC Purchases New Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

AlphaCentric Advisors LLC purchased a new stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 46,913 shares of the biotechnology company's stock, valued at approximately $234,000. AlphaCentric Advisors LLC owned 0.08% of Aldeyra Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of ALDX. State Street Corp grew its position in Aldeyra Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 973,908 shares of the biotechnology company's stock valued at $5,249,000 after buying an additional 16,188 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Aldeyra Therapeutics by 163.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company's stock valued at $2,571,000 after acquiring an additional 295,864 shares in the last quarter. Barclays PLC increased its stake in shares of Aldeyra Therapeutics by 280.1% during the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company's stock valued at $353,000 after acquiring an additional 48,313 shares during the period. International Assets Investment Management LLC raised its holdings in Aldeyra Therapeutics by 397.0% during the third quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company's stock worth $15,480,000 after purchasing an additional 229,487 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in Aldeyra Therapeutics by 14.4% in the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 2,822 shares during the period. 59.71% of the stock is currently owned by institutional investors.

Aldeyra Therapeutics Stock Down 0.9 %

Shares of ALDX stock traded down $0.06 during mid-day trading on Thursday, hitting $6.72. 263,980 shares of the stock traded hands, compared to its average volume of 350,818. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. The company's 50-day simple moving average is $5.32 and its 200-day simple moving average is $5.28. Aldeyra Therapeutics, Inc has a twelve month low of $2.71 and a twelve month high of $6.92.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.